Bioinformatics Profiling of Five Immune-Related lncRNAs for a Prognostic Model of Hepatocellular Carcinoma

Abstract

Hepatocellular carcinoma (HCC), one of the most common tumors worldwide, has the fifth highest mortality rate, which is increasing every year. At present, many studies have revealed that immunotherapy has an important effect on many malignant tumors. The main purpose of our research was to verify and establish a new immune-related lncRNA model and to explore the potential immune mechanisms. We analysed the pathways and mechanisms of immune-related lncRNAs by bioinformatics analysis, screened key lncRNAs based on Cox regression analysis, and determined the characteristics of the immune-related lncRNAs. On this basis, a predictive model was established. Through a comparison of specificity and sensitivity, we found that the constructed model was superior to the known markers of HCC. Then, the cell types were identified by the relative subgroup (CIBERSORT) algorithm for RNA transcripts. A signature model was eventually constructed, and we proved that it was a survival factor for HCC. Moreover, five kinds of immune cells were significantly positively correlated with the signature. The results indicated that these five kinds of lncRNAs may be related to the immune infiltration of hepatocellular carcinoma. To verify these findings, we selected the top coexpressed lncRNA, AC099850.3, for further study. We found that AC099850.3 could promote the migration and proliferation of hepatocellular carcinoma cells in vitro. RT-PCR experiments found that AC099850.3 could promote the expression of the cell cycle molecules BUB1, CDK1, PLK1, and TTK, and western blotting to prove that the expression of the molecules CD155 and PD-L1 was inhibited in the interference group. In conclusion, we used five kinds of immune-related lncRNAs to construct prognostic signatures to explore the mechanism, which provides a new way to study therapies for HCC.

Constructing a Novel Signature and Predicting the Immune Landscape of Colon Cancer Using N6-Methylandenosine-Related lncRNAs

“…AL137782.1 and AC073896.3 are protective factors for colon cancer, which is consistent with our study [38]. Recently, AC099850.3 was proven to be involved in the migration and proliferation of hepatocellular carcinoma by regulating the expression of cell-cycle-related molecules [39]. In addition, AC099850.3was highly expressed in HCC and squamous cell carcinoma of the tongue and increased the predicted value of the signature through coexpression and the ceRNA mechanism [40][41][42][43].…”

A Novel Necroptosis-Related lncRNA Signature Predicts the Prognosis of Lung Adenocarcinoma

“…We conducted univariate, LASSO, and multivariate Cox regression analyses and identified seven NRlncRNAs (AC026355.2, AC099850.3, AF131215.5, UST-AS2, ARHGAP26-AS1, FAM83A-AS1, and AC010999.2) significantly linked to the OS of LUAD patients to construct the necroptosis-related lncRNA signature. Among those lncRNAs, AC099850.3 has been reported to be highly expressed in tumors and closely related to the development and procession of NSCLC ( Zhou et al, 2021 ); AC099850.3 is demonstrated to promote proliferation and migration in hepatocellular carcinoma and is also an important member of the prognosis model in hepatocellular carcinoma and colorectal cancer ( Wu et al, 2021 ; Zhang et al, 2021 ). AF131215.5 also represented the independent prognostic significance of OS in patients with LUAD ( Hou and Yao, 2021 ).…”

Selection of lncRNAs That Influence the Prognosis of Osteosarcoma Based on Copy Number Variation Data

“…To our knowledge, lncRNA PSMB1 is the first to be found in cancers, while AC129492.1 and AC037459.4 have been reported in other cancers. For instance, AC129492.1 is associated with the prognosis of hepatocellular carcinoma and may regulate immune response in hepatocellular carcinoma [ 24 ]. Moreover, Yin et al also found that AC129492.1 can affect the prognosis in colon cancer and may be involved in the regulation of genome instability [ 25 ].…”